OBJECTIVES: We aimed to assess the long-term safety and tolerability of imatinib in diffuse cutaneous systemic sclerosis (dcSSc). METHODS: In this open-label, single-arm, extension-phase clinical trial, patients continued imatinib for 24 months following 12 months of initial treatment. RESULTS:Seventeen patients were enrolled. Forty of 92 adverse events (AE) and 0/6 serious (S) AEs were possibly related to medication. The MRSS decreased from a median of 21 to 16, (p=0.002). CONCLUSIONS: This study demonstrates long-term safety and tolerability of imatinib in a substantial proportion of patients with dcSSc. This is important in evaluating the relevance of this therapy in a chronic disease such as SSc.
RCT Entities:
OBJECTIVES: We aimed to assess the long-term safety and tolerability of imatinib in diffuse cutaneous systemic sclerosis (dcSSc). METHODS: In this open-label, single-arm, extension-phase clinical trial, patients continued imatinib for 24 months following 12 months of initial treatment. RESULTS: Seventeen patients were enrolled. Forty of 92 adverse events (AE) and 0/6 serious (S) AEs were possibly related to medication. The MRSS decreased from a median of 21 to 16, (p=0.002). CONCLUSIONS: This study demonstrates long-term safety and tolerability of imatinib in a substantial proportion of patients with dcSSc. This is important in evaluating the relevance of this therapy in a chronic disease such as SSc.
Authors: Daniel N Reed; David L Hall; James H Cottle; Katherine Frimenko; Christina K Horton; Farah Abu Sharkh; Rachel Beckett; Brandon Hernandez; Hannah Mabe; Shadee T Mansour; Sebastian A Rodriguez; Bradley Weprin; Leigh E Yarborough Journal: Clin Case Rep Date: 2020-01-17
Authors: Emma Derrett-Smith; Kristina E N Clark; Xu Shiwen; David J Abraham; Rachel K Hoyles; Olivier Lacombe; Pierre Broqua; Jean Louis Junien; Irena Konstantinova; Voon H Ong; Christopher P Denton Journal: Arthritis Res Ther Date: 2021-09-06 Impact factor: 5.156